LRG Science Team

Home/LRG Science Team

About LRG Science Team

This author has not yet filled in any details.
So far LRG Science Team has created 44 blog entries.

New in SDH-Deficient Research – The Paraganglioma* Preclinical Project

The Pediatric SDH-Deficient GIST Consortium, which was launched at the Biden Cancer Summit, consists of an impressive team of researchers, clinicians, academics, and patient advocacy groups. A member of our consortium, Dr. Joshua D. [...]

By |2018-12-17T14:34:57-05:00December 17th, 2018|News, Newsletter, Research|

GIST Updates from the ASCO Annual Meeting 2018

Executive Director, Norman Scherzer, and Real World Evidence Data Scientist, Dr. Yu Wang, of the Life Raft Group recently attended the ASCO (American Society of Clinical Oncologists) 2018 meeting in Chicago. Dr. Wang describes [...]

By |2018-10-29T13:43:20-05:00June 18th, 2018|Clinical Trials, News, Research|

NIH Pediatric and Wildtype GIST Clinic Report: Surgical Management

A recent report from the National Institutes of Health Pediatric and Wildtype GIST Clinic, published in the Journal of Clinical Oncology suggests that surgical resection for wildtype GIST should be restricted to the initial [...]

By |2018-10-30T09:25:10-05:00January 10th, 2017|News, Research|

Important Research Study Holds Hope for “Quadruple Wildtype” GIST Patients

A recent study published in the Journal of Translational Medicine, presents important research findings for the 10-15% of GIST patients who lack mutations in KIT, PDGFRA, SDHX or RAS pathway indicators, the primary oncogenic [...]

By |2018-10-30T09:25:15-05:00January 6th, 2017|News, Research|

Loxo Oncology Announces Plans for LOXO-101

In a recent press release, Loxo Oncology announced an update on the status of their TRK (tropomyosin receptor kinase) inhibitor drug, larotrectinib (LOXO-101). Larotrectinib targets the NTRK genes, which encode for the TRK kinases. [...]

By |2018-10-30T09:25:21-05:00December 22nd, 2016|Clinical Trials, News, Research|

LOXO-101 receives breakthrough therapy designation from FDA for solid tumors with NTRK gene fusions

Loxo Oncology  announced in a press release that the FDA has granted breakthrough therapy designation to LOXO-101 for the treatment of unresectable or metastatic solid tumors with neurotrophic tyrosine receptor kinase gene fusions. This [...]

By |2018-10-30T09:38:38-05:00July 21st, 2016|News, Research|

Liquid Biopsy Holds Promise for Precision Medicine

In a recent release from the Translational Genomics Research Institute (TGen), it was reported that researchers have discovered that by analyzing circulating tumor DNA (ctDNA) through liquid biopsy that a patient's cancer can be tracked [...]

By |2018-10-30T11:23:07-05:00December 29th, 2015|News, Research|

New Study Reviews Follow-Up Treatment Strategies for GIST

In a recent article in the May 2015 edition of the European Journal of Cancer, Heikki Joensuu, one of the foremost authorities on adjuvant treatment for GIST, discussed how follow-up treatment is currently performed for [...]

By |2018-11-05T15:34:20-05:00June 30th, 2015|News, Research, Survival Strategies|

Regorafenib-Related Hand-Foot Skin Reaction

A recent comprehensive review of the literature of the PubMed database and of the clinical experiences of oncologists and dermatologists concerning patients with regorafenib (Stivarga) related hand-foot skin reaction (HFSR) was published in the [...]

By |2019-10-31T13:40:24-05:00June 26th, 2015|Coping with GIST, News, Side Effects|